Results 11 to 20 of about 227,695 (301)
Frontiers in Pharmacology, 2021 Hepatocellular carcinoma (HCC) is the most prevalent subtype of liver cancer with a mortality rate of approximately 3–6/100,000 and is the third leading cause of cancer-related death worldwide.
Haina Wang +13 more
doaj +1 more source
FHL2 regulates hematopoietic stem cell functions under stress conditions. [PDF]
, 2015 FHL2, a member of the four and one half LIM domain protein family, is a critical transcriptional modulator. Here, we identify FHL2 as a critical regulator of hematopoietic stem cells (HSCs) that is essential for maintaining HSC self-renewal under ...
Chen, J +12 more
core +2 more sources
Mesenchymal stem cells in hematopoietic stem cell transplantation [PDF]
Cytotherapy, 2009 Mesenchymal stromal/stem cells (MSC) of bone marrow (BM) origin not only provide the supportive microenvironmental niche for hematopoietic stem cells (HSC) but are capable of differentiating into various cell types of mesenchymal origin, such as bone, fat and cartilage.
Minoo, Battiwalla, Peiman, Hematti
openaire +2 more sources
Non-infectious pulmonary complications of hematopoietic stem cell transplantation [PDF]
, 2014 Noninfectious pulmonary complications of hematopoietic stem cell transplant are currently more prevalent than infectious complications. Unfortunately, the pathophysiology basis is not completely understood.
Baloglu, Orkun +2 more
core +1 more source
Journal of Hematology & Oncology, 2017 Background The optimal monitoring schedules and cutoff minimal residual disease (MRD) levels for the accurate prediction of relapse at all time points after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain unclear in patients with t ...
Ya-Zhen Qin +14 more
doaj +1 more source
Evidence that hematopoietic stem cell function is preserved during aging in long-lived S6K1 mutant mice [PDF]
, 2016 The mechanistic target of rapamycin (mTOR) signalling pathway plays a highly conserved role in aging; mice lacking ribosomal protein S6 kinase 1 (S6K1-/-) have extended lifespan and healthspan relative to wild type (WT) controls. Exactly how reduced mTOR
Irvine, Elaine E. +5 more
core +2 more sources
Experimental Hematology & Oncology, 2017 Background Ruxolitinib is a potent inhibitor of JAK1/2 with proven efficacy in myelofibrosis. In recent years, research in graft versus host disease (GVHD) has revealed the role of activation of JAK pathways in alloreactive lymphocytes. Some reports have
Mauricio Sarmiento Maldonado +7 more
doaj +1 more source
Hematopoietic cell differentiation from embryonic and induced pluripotent stem cells [PDF]
, 2013 Pluripotent stem cells, both embryonic stem cells and induced pluripotent stem cells, are undifferentiated cells that can self-renew and potentially differentiate into all hematopoietic lineages, such as hematopoietic stem cells (HSCs), hematopoietic ...
Inoue-Yokoo, Tomoko +4 more
core +1 more source
Journal of Hematology & Oncology, 2019 The original article [1] contains two errors in the MRD Testing sub-section of the Methods:
Chen-Hua Yan +13 more
doaj +1 more source
Experimental Hematology & Oncology, 2023 Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a refractory and recurrent subtype of B-cell ALL enriched with kinase-activating rearrangements.
Xuehong Zhang +13 more
doaj +1 more source